Künig et al. (36) evaluated in 14 patients with DRD, the dopamine D2-R binding by 11C-raclopride PET in comparison with 16 levodopa-treated Parkinson’s disease (PD) patients and 26 healthy controls (HCs). This evidence concerns the gene DRD2 and dystonia 5.